149 related articles for article (PubMed ID: 31386267)
1. Management of patients with gout and achievement of target serum urate levels at a tertiary rheumatology service in Australia.
Bavanendrakumar M; Robinson PC
Intern Med J; 2020 Mar; 50(3):337-341. PubMed ID: 31386267
[TBL] [Abstract][Full Text] [Related]
2. Monitoring and Achievement of Target Serum Urate Among Gout Patients Receiving Long-Term Urate-Lowering Therapy in the American College of Rheumatology RISE Registry.
Hammam N; Li J; Kay J; Izadi Z; Yazdany J; Schmajuk G
Arthritis Care Res (Hoboken); 2023 Jul; 75(7):1544-1552. PubMed ID: 36039961
[TBL] [Abstract][Full Text] [Related]
3. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
Corbett EJM; Pentony P; McGill NW
Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
[TBL] [Abstract][Full Text] [Related]
4. Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort.
Singh JA; Yang S; Saag KG
J Rheumatol; 2020 Mar; 47(3):449-460. PubMed ID: 31416925
[TBL] [Abstract][Full Text] [Related]
5. Serum urate levels and therapy in adults treated with long-term dialysis: a retrospective cross-sectional study.
Yeo E; Palmer SC; Chapman PT; Frampton C; Stamp LK
Intern Med J; 2019 Jul; 49(7):838-842. PubMed ID: 30426652
[TBL] [Abstract][Full Text] [Related]
6. Burden and management of gout in a multi-ethnic Asian cohort.
Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
[TBL] [Abstract][Full Text] [Related]
7. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
Stamp LK; Barclay ML; O'Donnell JL; Zhang M; Drake J; Frampton C; Chapman PT
Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population.
Pui K; Gow PJ; Dalbeth N
J Rheumatol; 2013 Jun; 40(6):872-6. PubMed ID: 23457380
[TBL] [Abstract][Full Text] [Related]
9. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
10. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
11. Using electronic visits (E-visits) to achieve goal serum urate levels in patients with gout in a rheumatology practice: A pilot study.
Yokose C; Jorge A; D'Silva K; Serling-Boyd N; Matza M; Nasrallah M; Keller S; Oza A; Choi H; Bolster MB; Collier D
Semin Arthritis Rheum; 2020 Dec; 50(6):1382-1386. PubMed ID: 32359694
[TBL] [Abstract][Full Text] [Related]
12. Why Do Patients With Gout Not Take Allopurinol?
Emad Y; Dalbeth N; Weinman J; Chalder T; Petrie KJ
J Rheumatol; 2022 Jun; 49(6):622-626. PubMed ID: 35169055
[TBL] [Abstract][Full Text] [Related]
13. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
[TBL] [Abstract][Full Text] [Related]
14. Chronic gout: Barriers to effective management.
Rogenmoser S; Arnold MH
Aust J Gen Pract; 2018 Jun; 47(6):351-356. PubMed ID: 29966174
[TBL] [Abstract][Full Text] [Related]
15. Gout in Dalarna, Sweden - a population-based study of gout occurrence and compliance to treatment guidelines.
Sigurdardottir V; Svärd A; Jacobsson L; Dehlin M
Scand J Rheumatol; 2023 Sep; 52(5):498-505. PubMed ID: 36300710
[TBL] [Abstract][Full Text] [Related]
16. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
[TBL] [Abstract][Full Text] [Related]
17. Patients with severe gout treated in mixed settings.
Rasmussen C; Larsen MB; Linauskas A
Dan Med J; 2021 Oct; 68(11):. PubMed ID: 34983730
[TBL] [Abstract][Full Text] [Related]
18. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
Feng X; Li Y; Gao W
Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of Urate-Lowering Therapy Among US Veterans Following the 2012 American College of Rheumatology Guidelines for Management of Gout.
Hughes JC; Wallace JL; Bryant CL; Salvig BE; Fourakre TN; Stone WJ
Ann Pharmacother; 2017 Apr; 51(4):301-306. PubMed ID: 27881692
[TBL] [Abstract][Full Text] [Related]
20. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout.
Perez-Ruiz F; Calabozo M; Pijoan JI; Herrero-Beites AM; Ruibal A
Arthritis Rheum; 2002 Aug; 47(4):356-60. PubMed ID: 12209479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
